DK0880588T3 - Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium - Google Patents

Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium

Info

Publication number
DK0880588T3
DK0880588T3 DK97905212.3T DK97905212T DK0880588T3 DK 0880588 T3 DK0880588 T3 DK 0880588T3 DK 97905212 T DK97905212 T DK 97905212T DK 0880588 T3 DK0880588 T3 DK 0880588T3
Authority
DK
Denmark
Prior art keywords
plasmodium
msp
recombinant protein
terminal fragment
protein containing
Prior art date
Application number
DK97905212.3T
Other languages
English (en)
Inventor
Charles Roth
Shirley Longacre-Andre
Faridabano Nato
John W Barnwell
Kamini Mendis
Original Assignee
Pasteur Institut
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ New York filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK0880588T3 publication Critical patent/DK0880588T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97905212.3T 1996-02-14 1997-02-14 Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium DK0880588T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9601822A FR2744724B1 (fr) 1996-02-14 1996-02-14 Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
PCT/FR1997/000290 WO1997030158A2 (fr) 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium

Publications (1)

Publication Number Publication Date
DK0880588T3 true DK0880588T3 (da) 2010-05-17

Family

ID=9489188

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905212.3T DK0880588T3 (da) 1996-02-14 1997-02-14 Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium

Country Status (14)

Country Link
US (5) US6958235B1 (da)
EP (2) EP2194132A1 (da)
JP (1) JP2000516083A (da)
KR (1) KR20000065266A (da)
CN (2) CN1276975C (da)
AT (1) ATE456658T1 (da)
AU (1) AU1884197A (da)
CA (1) CA2241802A1 (da)
DE (1) DE69739749D1 (da)
DK (1) DK0880588T3 (da)
ES (1) ES2338832T3 (da)
FR (1) FR2744724B1 (da)
PT (1) PT880588E (da)
WO (1) WO1997030158A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
US8188213B2 (en) 1996-02-14 2012-05-29 Institut Pasteur Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
EP1808443A1 (en) * 2006-01-13 2007-07-18 Institut Pasteur Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP1025244A2 (en) 1997-10-20 2000-08-09 Genzyme Transgenics Corporation NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
JP2002543774A (ja) * 1999-04-20 2002-12-24 メディカル リサーチ カウンシル ワクチン
AU1600401A (en) * 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
AR027370A1 (es) * 2000-02-17 2003-03-26 Lg Chemical Ltd Inmunoensayo y reactivo de diagnostico para malaria, y correspondientes metodos de preparacion, vectores de expresion y transformantes
KR100373918B1 (ko) * 2000-02-17 2003-02-26 주식회사 엘지생명과학 말라리아의 효소 면역학적 측정방법 및 이에 사용되는진단시약
KR100427513B1 (ko) * 2000-02-17 2004-04-30 주식회사 엘지생명과학 말라리아 특이 면역글로블린 엠의 검출에 의한 말라리아의면역학적 측정방법, 진단시약 및 진단방법
CN1176945C (zh) * 2001-02-01 2004-11-24 中国人民解放军第二军医大学 疟原虫融合抗原及其制法和用途
DK1350839T3 (da) 2002-04-05 2010-07-12 Pasteur Institut Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti
WO2005014654A2 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a c4bp core protein and a monomeric antigen, and its use
DK1526178T3 (da) * 2003-10-24 2010-01-18 Pasteur Institut MSP-3-lignende genfamilie
EP1529536A1 (en) * 2003-11-05 2005-05-11 Institut Pasteur Immunogenic composition having improved immunostimulation capacity
WO2008059314A1 (es) * 2006-11-14 2008-05-22 Centro Internacional De Vacunas Vacuna contra la malaria, basada en la subunidad 200l de la proteína msp1 de plasmodium vivax
WO2010036293A1 (en) * 2008-09-24 2010-04-01 The Johns Hokins University Malaria vaccine
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
CN101921337B (zh) * 2010-07-21 2013-05-08 上海市疾病预防控制中心 间日疟原虫乳酸脱氢酶抗体、相关制备方法、杂交瘤细胞株和应用
CN103965327B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
WO2015055772A1 (en) 2013-10-16 2015-04-23 Shirley Longacre Combination of plasmodium merozoite surface proteins msp4 and 1 and uses thereof
WO2015056244A1 (pt) * 2013-10-18 2015-04-23 Universidade Federal De Minas Gerais - Ufmg Kit e método imunodiagnóstico para detecção de anemia em decorrência de malária vivax, peptídeos sintéticos e usos
WO2018130871A1 (en) * 2016-12-23 2018-07-19 The Walter And Eliza Hall Institute Of Medical Research System, method, apparatus and diagnostic test for plasmodium vivax
JP7134461B2 (ja) * 2018-03-23 2022-09-12 国立大学法人金沢大学 マラリア治療剤、マラリア予防剤及び抗マラリア自然免疫賦活剤
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用
CN111978413B (zh) * 2020-08-21 2022-04-15 江南大学 一种体外抑制食蟹猴疟原虫生长的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
EP0154454B1 (en) * 1984-02-22 1991-07-03 The Wellcome Foundation Limited Cloning of dna for protozoal antigens
US4937016A (en) * 1989-02-01 1990-06-26 Dai-Ichi Kogyo Seiyaku Co., Ltd. Copper conductor composition
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
GB9203821D0 (en) * 1992-02-22 1992-04-08 Medical Res Council Improvements in or relating to malaria vaccine
EP0621337A1 (en) * 1993-01-25 1994-10-26 American Cyanamid Company Codon optimized DNA sequence for insect toxin AaIT
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
FR2744724B1 (fr) 2002-08-02
AU1884197A (en) 1997-09-02
US7696308B2 (en) 2010-04-13
KR20000065266A (ko) 2000-11-06
EP0880588B1 (fr) 2010-01-27
WO1997030158A9 (fr) 1999-06-24
FR2744724A1 (fr) 1997-08-14
US20060018932A1 (en) 2006-01-26
CN1222936A (zh) 1999-07-14
EP2194132A1 (fr) 2010-06-09
CN101230104A (zh) 2008-07-30
EP0880588A2 (fr) 1998-12-02
US20100291133A1 (en) 2010-11-18
PT880588E (pt) 2010-03-22
WO1997030158A2 (fr) 1997-08-21
ATE456658T1 (de) 2010-02-15
DE69739749D1 (de) 2010-03-18
CN1276975C (zh) 2006-09-27
US20020076403A1 (en) 2002-06-20
US6958235B1 (en) 2005-10-25
WO1997030158A3 (fr) 1997-10-23
US20070036818A1 (en) 2007-02-15
ES2338832T3 (es) 2010-05-12
CA2241802A1 (fr) 1997-08-21
JP2000516083A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
DK0880588T3 (da) Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium
Sinigaglia et al. Epitopes recognized by human T lymphocytes on malaria circumsporozoite protein
ATE263243T1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
ATE411043T1 (de) Verfahren von dna-impfung
PE97298A1 (es) Composicion para vacunas
Nudelman et al. Dual action of anti-sporozoite antibodies in vitro.
Krettli et al. Malaria: a sporozoite runs through it
DK424988A (da) Specifikke ekskretion -sekretion-antigener af toxoplasma gondii, ekspressionsprodukter deraf, fremgangsmaade til fremstilling deraf og diagnostiske og profylaktiske anvendelser deraf
WO2002070542A3 (en) Band 3 antigenic peptides, malaria polypeptides and uses thereof
DK0485388T3 (da) Vaccine til immunisering af katte mod udskillelse af toxoplasma-oocyster
Cochrane et al. A circumsporozoite-like protein is present in micronemes of mature blood stages of malaria parasites
Vergara et al. Conserved group-specific epitopes of the circumsporozoite proteins revealed by antibodies to synthetic peptides.
CA2089660A1 (en) New peptides and their use
DK36988A (da) Ekspression af p.falciparum-circumsporozoitprotein af gaer
Vergara et al. Multiple non-repeated epitopes on the circumsporozoite protein of Plasmodium knowlesi
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
ATE123302T1 (de) Rhoptry-membran-antigen von -i(plasmodium falciparum).
ES2009587A6 (es) Un metodo para purificar un polipeptido.
SE8803062D0 (sv) Sequential polypeptides endowed with immunological activity
US5178861A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
WO2001013923A1 (en) Malaria gpi anchors as vaccines anti-parasitic drugs and for use in diagnostics
Etlinger The Use of Recombinant Proteins and Synthetic Peptides in the Development of a Plasmodium Falciparum Malaria Vaccine